Table 7 Costs, QALYs, and ICER per patient over a lifetime for finerenone + SoC and SoC
Finerenone + SoC | SoC | Difference | |
|---|---|---|---|
Costs within the healthcare system | |||
Medication costs | €10,098 | €6,554 | €3,545 |
CKD treatment | €4272 | €4,125 | €148 |
Dialysis | €57,650 | €65,584 | − €7,935 |
Transplant | €2262 | €2,125 | − €275 |
First CV event costs | €5843 | €6,134 | − €291 |
Subsequent CV event | €1528 | €1,633 | − €105 |
Hyperkalaemia leading to hospitalization | €159 | €88 | €70 |
Hyperkalaemia not leading to hospitalization | €192 | €126 | €66 |
New onset of atrial fibrillation | €168 | €198 | − €30 |
Indirect costs for patients and caregivers | €11,076 | €12,406 | − €1,329 |
Total costs (healthcare perspective) | €82,172 | €86,978 | − €4,708 |
Total costs (societal perspective) | €93,248 | €99,384 | − €6,136 |
Total effects (life-years without CV) | 7.43 | 7.13 | 0.30 |
Total effects (life-years without RRT) | 8.65 | 8.34 | 0.31 |
Total effects (life-years) | 9.40 | 9.18 | 0.22 |
Total effects (QALY) | 7.05 | 6.85 | 0.20 |
ICER (costs/QALY) | Finerenone + SoC is a dominant treatment option | ||